Protocolo de terapéutica antitrombótica de la fibrilación auricular

  1. Rubio Campal, J.M. 1
  2. Sáchez Borque, P. 1
  3. Bravo Calero, L. 1
  4. Miracle Blanco, A. 1
  5. Porta Sánchez, A. 2
  6. Cabrera Rodríguez, J.A. 2
  1. 1 Servicio de Cardiología, Hospital Universitario Fundación Jiménez Díaz. Universidad Autónoma de Madrid, Madrid, España
  2. 2 Servicio de Cardiología, Hospital Universitario Quirónsalud Madrid. Universidad Europea de Madrid. Pozuelo de Alarcón, Madrid, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Enfermedades cardiovasculares (XI)

Series: 13

Issue: 45

Pages: 2649-2652

Type: Article

DOI: 10.1016/J.MED.2021.11.006 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Atrial fibrillation is the most frequent of all arrhythmias and is associated with a significant increase in morbidity and mortality. Its presence in turn significantly increases the presence of embolic phenomena. Therefore, preventing these embolic phenomena is currently a first line of therapy. There are validated thrombotic and hemorrhagic risk scales that indicate which patients should be anticoagulated and with what type of drugs. These scales and indications are clear, precise, and must be known and used by all physicians. Currently, direct oral anticoagulants have entailed a change in the prophylactic management of embolic events in subjects with this arrhythmia versus the classic antivitamin K drugs.

Bibliographic References

  • Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomström Lundqvist, C. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Eur Heart J., 42 (5) (2021), pp. 373-498
  • Steffel, J., Verhamme, P., Potpara, T.S., Albaladejo, P., Antz, M., Desteghe, L. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation Eur Heart J., 39 (2018), pp. 1330-1393
Data source: Dialnet